Literature DB >> 3207504

Immunological relationships between rabies virus and rabies-related viruses studied with monoclonal antibodies to Mokola virus.

J Vincent1, F Bussereau, P Sureau.   

Abstract

Specific monoclonal antibodies (mAb) were prepared against a rabies-related lyssavirus, Mokola virus. A strain isolated in the Central African Republic, Mok-3, was used as immunogen. After 3 fusions more than 90 hybridoma cultures secreting mAb were identified. According to their different patterns of reactivity against rabies and rabies-related viruses, 61 ascites fluids were obtained. The antibody class was IgM for 2 of them and IgG for 59. They were specific for one of the 4 major viral proteins, as determined by immunofluorescence, neutralization and immunoblotting tests. Their patterns of reactivity were determined against 6 different strains of rabies-related viruses: Lagos-bat virus from Nigeria (Lag-1) and the Central African Republic (Lag-2), Duvenhage virus from the Republic of South Africa (Duv-1) and Federal Republic of Germany (Duv-3), Mokola virus from Nigeria (Mok-1) and Cameroon (Mok-2) and a fixed strain of rabies virus, the challenge virus strain (CVS). According to their reactivities with these strains and the pattern of fluorescence, the mAb were classified into 11 different groups with intracytoplasmic fluorescence and 7 groups with cell surface fluorescence. A differential diagnosis of these lyssaviruses is possible in tissue culture using some of these mAb.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3207504     DOI: 10.1016/s0769-2617(88)80014-5

Source DB:  PubMed          Journal:  Ann Inst Pasteur Virol        ISSN: 0769-2617


  2 in total

1.  Monoclonal antibodies to Mokola virus for identification of rabies and rabies-related viruses.

Authors:  F Bussereau; J Vincent; D Coudrier; P Sureau
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

Review 2.  Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses.

Authors:  Venice Du Pont; Richard K Plemper; Matthias J Schnell
Journal:  Curr Opin Virol       Date:  2019-02-10       Impact factor: 7.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.